Compare · MGTX vs RGNX
MGTX vs RGNX
Side-by-side comparison of MeiraGTx Holdings plc (MGTX) and REGENXBIO Inc. (RGNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MGTX and RGNX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MGTX is the larger of the two at $1.43B, about 2.4x RGNX ($588.2M).
- Over the past year, MGTX is up 94.1% and RGNX is up 2.8% - MGTX leads by 91.2 points.
- RGNX has been more active in the news (11 items in the past 4 weeks vs 9 for MGTX).
- RGNX has more recent analyst coverage (23 ratings vs 3 for MGTX).
- Company
- MeiraGTx Holdings plc
- REGENXBIO Inc.
- Price
- $14.55-2.35%
- $9.39+5.39%
- Market cap
- $1.43B
- $588.2M
- 1M return
- +23.24%
- -2.29%
- 1Y return
- +94.07%
- +2.85%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2015
- News (4w)
- 9
- 11
- Recent ratings
- 3
- 23
MeiraGTx Holdings plc
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was incorporated in 2015 and is based in New York, New York.
REGENXBIO Inc.
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II; RGX-111, which is in Phase I clinical trial for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop vectorized antibodies for the treatment of neurodegenerative diseases. The company was formerly known as ReGenX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Latest MGTX
- Graviton BioScience Corporation Announces Publication of Positive Ph1b Trial Results for GV101 (TDI01) in Chronic Graft versus Host Disease in Signal Transduction and Targeted Therapy, by Beijing Tide Pharmaceutical
- PRESIDENT & CEO Forbes Alexandria sold $859,320 worth of Ordinary Shares (62,000 units at $13.86) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 1,325,695 units (SEC Form 4)
- SEC Form 144 filed by MeiraGTx Holdings plc
- SEC Form S-8 filed by MeiraGTx Holdings plc
- SEC Form 10-Q filed by MeiraGTx Holdings plc
- MeiraGTx Holdings plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- MeiraGTx Reports Second Quarter 2026 Financial and Operational Results
- Graviton BioScience Announces Clearance of Investigational New Drug (IND) for GV101 for the Treatment of Friedreich's Ataxia
- MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- CFO & COO Giroux Richard sold $700,560 worth of Ordinary Shares (56,000 units at $12.51) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 908,530 units (SEC Form 4)
Latest RGNX
- REGENXBIO Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
- REGENXBIO Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- REGENXBIO Announces Regulatory Update on RGX-121 for MPS II
- REGENXBIO downgraded by Barclays with a new price target
- SEC Form 10-Q filed by REGENXBIO Inc.
- REGENXBIO Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
- Chief Medical Officer Pakola Steve covered exercise/tax liability with 7,468 shares, decreasing direct ownership by 4% to 205,541 units (SEC Form 4)
- Chief Strategy & Legal Officer Christmas Patrick J. covered exercise/tax liability with 4,699 shares, decreasing direct ownership by 2% to 205,968 units (SEC Form 4)